General InformationNurExone Biologic Inc. is a Maryland-based clinical-stage biotech company founded in 2010 with 11-50 employees developing exosome-based therapeutics for nervous system regeneration.
Funding & FinancialsThe company has raised multiple rounds of funding including Series B financing, with total funding in the range of $20-30M from investors including Tarveda Capital and other institutional backers.
Leadership & TeamFounded and led by experienced biotech entrepreneurs with expertise in regenerative medicine and stem cell biology; specific current CEO details require confirmation from recent company updates.
Recent ActivityNurExone is advancing its ExoTherapy™ platform through clinical trials for spinal cord injury and has been expanding its intellectual property portfolio around exosome-based nervous system therapies in recent years.